800 million yuan for growth hormone deployment

shapanqqcceqd · Post by **shapanqqcceqd** » Mon Jan 20, 2025 7:19 am

Shengxiang Biotech acquires Zhongshan Haiji

The first cross-border acquisition order of the new year has arrived.

The latest public announcement from Shengxiang Biotech shows that the company plans to acquire 100% equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. ("Zhongshan Haiji") for 807.5 million yuan in cash. After the transaction is completed, Zhongshan Haiji will become a wholly-owned subsidiary of the company.

The company stated that this acquisition is to actively implement the country’s call for children’s health management and promote long-term balanced development of the population. At the same time, it will use the company’s business advantages in the field of in vitro diagnostics and Zhongshan Haiji in the field of growth hormone to promote the company’s “diagnosis and treatment integration” Comprehensive strategic layout to enhance the company's profitability.

However, competition on the growth hormone track is becoming uk whatsapp mobile phone number list increasingly fierce. Some institutions predict that the global market size will be approximately US$3.4 billion in 2022, with a compound annual growth rate of approximately 8.1%, and is expected to reach a market size of US$7.3 billion by 2032. The Chinese market is also showing a trend of rapid growth. In 2021, the size of China's growth hormone market has exceeded 10 billion yuan, and in 2022 it will exceed 12 billion yuan.

As parents pay more attention to childhood dwarfism and medical technology continues to advance, it is expected that the penetration rate of growth hormone will increase to about 10% in the next 5-10 years, which will bring huge market growth space to the growth hormone industry.

This time, Shengxiang Biotech has set its sights directly on the field of biologics in the pharmaceutical field.

According to public reports, Shengxiang Biotech plans to acquire 100% equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. for 807.5 million yuan in cash.